| scholarly article | Q13442814 |
| P50 | author | Matteo Caleo | Q56449363 |
| Alessia Fabbri | Q73283729 | ||
| P2093 | author name string | Francesco Olimpico | |
| Federica Maltese | |||
| Mario Costa | |||
| Laura Baroncelli | |||
| Eleonora Vannini | |||
| P2860 | cites work | Quantitative kinematic characterization of reaching impairments in mice after a stroke. | Q38418257 |
| Electrophysiology of glioma: a Rho GTPase-activating protein reduces tumor growth and spares neuron structure and function. | Q38764612 | ||
| A Combined Approach Employing Chlorotoxin-Nanovectors and Low Dose Radiation To Reach Infiltrating Tumor Niches in Glioblastoma | Q38805579 | ||
| Mapping neuroplastic potential in brain-damaged patients | Q39970725 | ||
| Health-related quality of life in patients with glioblastoma: a randomised controlled trial | Q40368396 | ||
| Flavopiridol inhibits the growth of GL261 gliomas in vivo: implications for malignant glioma therapy | Q40601313 | ||
| Activation of Rho GTPases triggers structural remodeling and functional plasticity in the adult rat visual cortex | Q42621359 | ||
| Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. | Q45761249 | ||
| Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. | Q45862727 | ||
| The relationship between PSD-95 clustering and spine stability in vivo. | Q46706131 | ||
| Early environmental enrichment moderates the behavioral and synaptic phenotype of MeCP2 null mice | Q48299153 | ||
| Brain meningioma in a patient with complaints of low back pain and leg weakness | Q48307957 | ||
| Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells | Q48683084 | ||
| A robotic system for quantitative assessment and poststroke training of forelimb retraction in mice. | Q48880783 | ||
| Toxin-induced activation of the G protein p21 Rho by deamidation of glutamine. | Q54564124 | ||
| Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. | Q55475056 | ||
| Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas | Q30278053 | ||
| Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice | Q30636900 | ||
| Reducing GABAA-mediated inhibition improves forelimb motor function after focal cortical stroke in mice | Q30830054 | ||
| Tests to assess motor phenotype in mice: a user's guide | Q33464903 | ||
| CNF1 improves astrocytic ability to support neuronal growth and differentiation in vitro. | Q34241648 | ||
| Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches | Q34515465 | ||
| Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy | Q34531947 | ||
| The Organization of the Forelimb Representation of the C57BL/6 Mouse Motor Cortex as Defined by Intracortical Microstimulation and Cytoarchitecture | Q34691597 | ||
| The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma | Q35053326 | ||
| The bacterial protein toxin, cytotoxic necrotizing factor 1 (CNF1) provides long-term survival in a murine glioma model | Q35189981 | ||
| Incidence of gliomas by anatomic location | Q35870508 | ||
| Motor deficits correlate with resting state motor network connectivity in patients with brain tumours | Q35888660 | ||
| High grade glioma: imaging combined with pathological grade defines management and predicts prognosis | Q37012633 | ||
| Post-stroke protection from maladaptive effects of learning with the non-paretic forelimb by bimanual home cage experience in C57BL/6 mice | Q37093185 | ||
| Cytotoxic Necrotizing Factors (CNFs)-A Growing Toxin Family | Q37954268 | ||
| Diffuse low-grade gliomas and neuroplasticity | Q38248884 | ||
| The Rho-deamidating cytotoxic necrotizing factor 1 from Escherichia coli possesses transglutaminase activity. Cysteine 866 and histidine 881 are essential for enzyme activity | Q38337026 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 23539-23550 | |
| P577 | publication date | 2017-04-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Progression of motor deficits in glioma-bearing mice: impact of CNF1 therapy at symptomatic stages | |
| P478 | volume | 8 |
| Q60912216 | A Nervous System-Specific Model of Creatine Transporter Deficiency Recapitulates the Cognitive Endophenotype of the Disease: a Longitudinal Study |
| Q55456919 | Bacterial Toxins and Targeted Brain Therapy: New Insights from Cytotoxic Necrotizing Factor 1 (CNF1). |
| Q58773484 | Circular RNA Complement Factor H (CFH) Promotes Glioma Progression by Sponging miR-149 and Regulating AKT1 |
| Q64891270 | Image and motor behavior for monitoring tumor growth in C6 glioma model. |
| Q99630184 | Micheliolide suppresses the viability, migration and invasion of U251MG cells via the NF-κB signaling pathway |
| Q102379423 | Proteomics analysis of serum small extracellular vesicles for the longitudinal study of a glioblastoma multiforme mouse model |
Search more.